SCHEMBL4496546

SCHEMBL4496546

CCOC(=O)c1cccc(OCC(=O)O)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.58
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
MAPT P10636 1/20 0.54
PKM P14618 1/20 0.53
HTT P42858 1/20 0.53
POLB P06746 1/20 0.53
MAPK1 P28482 1/20 0.52
ALOX15 P16050 1/20 0.51
PPARG P37231 1/20 0.51
PPARA Q07869 1/20 0.51
F2 P00734 1/20 0.51
F10 P00742 1/20 0.51
KDM4E B2RXH2 1/20 0.50
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182390 0.88 PPARA (0.58) TDP1L3MBTL1KMT2AMEN1MAPT
SCHEMBL1989713 0.87 KMT2A (0.62) LMNATDP1L3MBTL1KMT2AMEN1
SCHEMBL4508445 0.87 TDP1 (0.53) TDP1L3MBTL1KMT2AMEN1MAPT
SCHEMBL321575 0.84 LMNA (0.66) LMNAKMT2AMEN1MAPTPKM
SCHEMBL931897 0.83 KMT2A (0.69) LMNATDP1L3MBTL1KMT2AMEN1
SCHEMBL18703863 0.82 KMT2A (0.61) LMNATDP1KMT2AMAPTMAPK1
SCHEMBL340106 0.82 MAOB (0.69) KMT2AMEN1MAPTPKMCYP4F2
SCHEMBL5221473 0.82 TDP1 (0.66) TDP1L3MBTL1KMT2AMEN1MAPT
SCHEMBL4898454 0.81 LMNA (0.61) LMNAKMT2AMEN1PKMHTT
SCHEMBL9938318 0.81 MEN1 (0.70) LMNAKMT2AMEN1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 US disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 US disclosed
EP-1492537-A1 MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2005-01-05 EP disclosed
WO-2003082294-A1 MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 LMNA 3360/4885TDP1 4719/4885L3MBTL1 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.